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The aetiology of inflammatory bowel disease (IBD) remains obscure, currently thought to be 
associated with a genetic predisposition, dysregulation of the mucosal immune system, and a 
loss of antigen tolerance to enteric microflora, further influenced by a range of other 
environmental factors.  In many cases, disease activity can be unremitting and refractory to 
treatment, with an unpredictable response to conventional therapy. To this end, new treatment 
strategies are being pursued on the basis of our understanding of IBD pathogenesis, and there 
is increasing evidence that at least some components of the enteric flora are primary 
contributors. Restoring the balance of the colonic microbiota to a less-pathogenic state is 
therefore a desirable strategy. Probiotics are currently defined as live non-pathogenic micro-
organisms that, when ingested, exert a positive influence on host health beyond basic 
nutrition. On this basis, probiotics hold the potential to restore normal intestinal homeostasis. 
Despite more than a century of anecdotal reports of probiotic efficacy in gastrointestinal 
disease, only relatively recently have well-controlled, scientific studies and clinical trials, 
been conducted. Whilst reliable in vitro predictors of potential in vivo efficacy of putative 
probiotics await development, well-characterised animal model systems are proving valuable 
for the methodical, pre-clinical development of probiotics. Although early probiotic 
applications focussed largely on lactic acid bacteria (lactobacilli) and bifidobacteria, the 
range of candidate probiotics has now expanded significantly. Successful clinical application 
of the probiotic formulation, VSL#3, for treatment of the pouchitis variant of IBD, has 
instilled new excitement into the applicability of probiotics to IBD treatment, and the 
potential importance of probiotic combinations. The availability of new recombinant 
methodologies to develop ‘designer’ probiotics, capable of synthesizing and secreting specific 
factors, ranging from vitamins through to antibodies, further broadens the scope for probiotic 
application in IBD. Indeed, there are encouraging reports that probiotics may not need to be 
viable, or even intact, to exert their beneficial effects, with reports of therapeutic benefit from 
bacterial components such as DNA.  In addition to the development of rigorous predictive 
systems to ascertain probiotic efficacy, challenges for the future will include determining the 
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optimal probiotic, or probiotic combination, and its timing of administration during phases of 
IBD relapse and remission. At present, our understanding of the intestinal microflora, and the 
importance of its composition and variability between individuals, is limited. However, once 
this understanding has been attained, strategically-designed probiotic formulations could 
ultimately be ‘tailored’ to suit individual IBD patients. 
 
Introduction 
Inflammatory bowel disease (IBD) is the collective term for a group of chronic, idiopathic 
inflammatory disorders that affect the gastrointestinal system.  Crohn's disease and ulcerative 
colitis (UC) are the most common and serious variants of IBD, together imposing significant 
patient morbidity, economic burden, and long-term healthcare dependence. The aetiology of 
inflammatory bowel disease (IBD) remains obscure, currently thought to be associated with a 
genetic predisposition, dysregulation of the mucosal immune system, and a range of other 
environmental factors (1). In many cases, disease activity can be unremitting, with an 
unpredictable response to conventional therapy. 
 
Considerable progress has been made in studies of IBD genetics over the last decade, and the 
complementary strategies of genome-wide scanning and candidate gene-directed studies have 
led to the identification of a number of genetic markers that appear to predict disease 
susceptibility and behaviour (2). Identification of genetic markers that predispose to 
inflammation (alleles DR2, DRB1*0103 and DRB1*12) and a Crohn’s disease susceptibility 
gene on chromosome 16 [NOD2/CARD 15: Nucleotide-binding oligomerization domain 
protein 2] has paved the way for exciting new developments in therapeutic approaches for 
IBD (3,4).  NOD2/CARD 15 is a cytosolic protein involved in intracellular recognition of 
microbes by sensing peptidoglycan fragments, and there is compelling evidence that it serves 
as an intracellular pattern recognition receptor to enhance host defence by inducing the 
production of antimicrobial peptides such as human beta-defensin-2 (5).  
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The characterisation of newly-identified NOD2/CARD-15 mutations is providing new 
information on the likely contribution of a defective host anti-microbial defence system to 
IBD aetiology and pathogenesis. This could have exciting implications for the use of 
candidate micro-organisms as a novel treatment strategy for IBD. Prospectively, this 
information would be particularly valuable when combined with a concomitant strategy to 
address the genetic basis of responsiveness to IBD therapy. Indeed, the spectrum of new 
treatment modalities for IBD has expanded exponentially in recent years (reviewed in 6). 
These genetic and genomic strategies could form the basis for better predicting the likelihood 
of responsiveness to newly-developed IBD therapies associated with the utilisation of micro-
organisms, or factors derived from such organisms. 
 
Probiotics 
Although under continual review, the generally agreed definition of probiotics encompasses 
"live micro-organisms which, when consumed in adequate amounts, confer a health benefit 
on the host beyond basic nutrition" (7). This definition, however, may prove to be too limited 
and the term ‘alimentary pharmabiotics’ has been coined to further encompass dead 
organisms, or bacterial constituents which may be genetically or otherwise modified, and may 
not necessarily be restricted to those of human origin. Lactobacilli (8,9) and bifidobacteria, 
(10) species are generally referred to as archetypical probiotics, with increasing reports of 
probiotic properties attributed to non-pathogenic Escherichia coli (11,12) and non-bacterial 
organisms, such as Saccharomyces boulardii (13).  Probiotics are thought to function through 
a number of different actions including: the production of antimicrobial agents such as 
bacteriocins, hydrogen peroxide and organic acids; blocking adhesion of pathogens or toxins 
to epithelial cells; providing antioxidant agents; and modulation of the immune system 
(14,15).  Although the current review focuses on probiotic effects in the context of IBD, the 
complex interplay of mechanisms associated with specific organisms, or combinations of 
probiotic organisms, extends to applications for a broader range of medical disorders. 
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Probiotics and IBD  
Perhaps not surprisingly, the idiopathic nature of IBD, combined with its profound 
inflammatory characteristics, has resulted in current therapeutic strategies being targeted, 
almost exclusively, at disease immunomodulation (16). Notwithstanding this historical 
approach, new treatment modalities are now being pursued on the basis of our increased 
understanding of IBD pathogenesis. To this end, there is accumulating evidence that at least 
some components of the enteric flora are primary contributors to the unrelenting intestinal 
inflammation so characteristic of IBD. In general terms, restoring the balance of the colonic 
microbiota to a ‘less-pathogenic’ state would appear a desirable preventative, or therapeutic, 
strategy.  However, before we consider probiotics as a potential therapeutic option in IBD, we 
should consider the resident enteric microflora and the potential impact of probiotic 
organisms in the context of IBD aetiology. 
 
The intestinal microbiota and IBD aetiology 
Although the intestinal flora is essential for host defence, some of its constituents may, in 
genetically susceptible hosts, become a risk factor for IBD, and it has been proposed that 
resident bacterial flora play a pivotal role in IBD pathogenesis (17). Mechanisms underlying 
the influence of the intestinal flora on mucosal homeostasis, mucosal protection, development 
and function of immune responses, and metabolism of fecal residue are undergoing increased 
scientific scrutiny. Strategies to enhance the beneficial properties of endogenous microflora, 
or alternatively, to minimise deleterious effects, represent a logical therapeutic approach, 
forming the basis for manipulation of the intestinal flora in IBD treatment (18). 
 
Nevertheless, it is important to understand that an inappropriate reaction to infection by a 
specific persistent pathogen has not yet been eliminated as a possible aetiological component 
in IBD. Indeed, Crohn’s disease and UC share histopathological similarities with defined 
intestinal infections, and occur in areas with highest luminal bacterial concentrations (17,18). 
Strengthened by the causative link between Helicobacter pylori and gastric ulceration (19), 
many microbial pathogens have been promoted as initiators and perpetuators of IBD.  Perhaps 
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Mycobacterium avium, subspecies paratuberculosis (MAP) provides the most persuasive 
evidence as a causative agent in IBD since it manifests a Crohn’s-like phenotype in livestock 
in the condition known as Jonne’s disease (20). Other potential pathogenic causes have 
included M. kansaii, Escherichia coli, Diplostreptococcus species, viral vectors (measles, 
RNA viruses), Listeria monocytogenes, Fusobacterium necrophorum, Chlamydia species, 
Pseudomona maltophila and Helicobacter hepaticus (21,22,23). Taken together, identified 
probiotics capable of altering the intestinal environment such that colonization by the 
aforementioned species is inhibited, would therefore appear to be a logical strategy in IBD. 
 
Antibiotics have a defined role in the management of IBD and its complications, although 
their long-term usage is undesirable due to the risk of toxicity, bacterial resistance and 
overgrowth. Nevertheless, it would be fair to state that the current weight of scientific 
literature identifying a single organism as causative of IBD, although highly desirable, is not 
particularly compelling.  Although several authorities, including the Joint Food and 
Agricultural Organization of the United Nations and the World Health Organization (24,25), 
have described selection criteria for probiotic organisms, to date, no reliable in vitro 
predictors of in vivo efficacy of putative probiotics have been identified. This has been 
compounded by the realization that individual probiotics do not appear to act through a single 
mechanism, further complicated by the likelihood that probiotic combinations, as opposed to 
specific candidates, may be indicated for certain disorders. Indeed, the mechanism of action 
of probiotics is likely to vary with different strains and may also be dependent on the clinical 
condition for which it is applied. Although well-characterised animal models are gaining 
momentum as predictive pre-clinical efficacy systems, a discussion of likely probiotic 
mechanisms is indicated.  
 
Mechanisms of probiotic action in IBD 
Although perhaps a little simplistic, the ability for probiotics to prevent or combat infections 
may be partially- or entirely dependent upon mutual competitive metabolic interactions with 
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potential pathogens, production of anti-microbial peptides such as bacteriocins (25) or 
inhibition of epithelial adherence and translocation by pathogens (26,27). Interestingly, 
Collado et al (28) reported that in general, bifidobacterial strains of animal origin 
demonstrated an improved capacity to inhibit and displace pathogens from human mucus than 
were human strains, further reporting that bifidobacteria were capable of producing 
antimicrobial peptides directed against Helicobacter pylori (29). Cross-species utilization of 
probiotics may therefore provide another important level of complexity for probiotic utility in 
clinical disorders such as IBD. In certain allergic disorders, including atopic eczema, 
probiotic influences on mucosal barrier function may be operative (30), whilst multiple 
mechanisms may account for anti-neoplastic effects (31).  
 
Probiotics, tolerance and the immune response 
Since control of bowel inflammation has generally been recognised as paramount in IBD, it is 
perhaps not surprising that down-regulation of mucosal inflammation has been identified as 
the primary focus of both conventional and probiotic-targeted therapy, fuelled by the 
cumulative clinical experience with anti-TNF based treatment successes (32).  
 
Rodents and humans are normally tolerant to autologous microbiota, and an association 
between breakdown of this tolerance and the development of chronic intestinal inflammation 
has been demonstrated (32). Potentially, pathological responses to components of the 
intestinal flora may occur under normal physiological conditions, but these may be 
suppressed by immunoregulatory mechanisms. In a recent review by Thompson-Chagoyán et 
al (33), 11 models of IBD have been described, in which inflammation was found to be 
dependent on the presence of normal flora; the absence of normal flora being associated with 
non-appearance of the condition (34,35,36,37). This phenomenon has been reported across 
species (mice, rats and guinea pigs), and to occur in manipulated organisms such as 
transgenic mice with targeted deletion of the T-cell receptor (TCRα), that spontaneously 
develop colitis in response to the gut microbiota (38). Mucosal inflammation in rats and mice 
with induced IBD has also been reported to respond to treatment with broad-spectrum 
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antibiotics (39). Moreover; in some animal model systems, colonisation with normal flora 
results in the rapid development of T-cell-mediated gut inflammation which can be 
transferred to other animals using activated T cells directed against enteric bacteria (40). 
Nevertheless, it appears that not all commensal bacteria have an equivalent ability to induce 
mucosal inflammation, which is also influenced by the host genetic background. 
 
Following cell surface recognition via Toll-like receptors (41), the anti-inflammatory effects 
of probiotics require signalling with the epithelium and hence, the mucosal immune system 
(42). Although transduction of bacterial signals into host immune responses presumably 
involves more than one pathway, NF-kappaB has been established as a central regulator of 
epithelial responses to invasive pathogens (43,44). Non-pathogenic components of the flora 
may attenuate pro-inflammatory responses by delaying degradation of IkappaB, the counter-
regulatory factor to NF-kappaB (44). Indeed, it may be that probiotic bifidobacteria and 
lactobacilli may not use the same mechanism to achieve their anti-inflammatory effects as 
other signal transduction pathways begin to emerge.  
 
Clearly, a better understanding of the interplay between prokaryotes and eukaryotes, and 
subsequent effects on metabolic activity, will facilitate our knowledge of probiotic 
mechanisms. Bacterial adjuvants, including peptidoglycan, lipopolysaccharide, and DNA 
(CpG) bind to membrane-bound Toll-like receptors (TLR-2, 4, and 9. respectively), or 
cytoplasmic (NOD1 and NOD2) receptors (pattern recognition receptors), that activate 
nuclear factor-kappaB and transcription of many proinflammatory cytokines (45). Prokaryotic 
DNA perhaps represents the first description of a growing number of bacteria-sourced factors 
with the potential to alter host epithelial and mucosal immune responses. Un-methylated 
cytosine–guanine (CpG)-containing DNA, the ligand for Toll-like receptor 9 (TLR9), is a 
recently recognized microbial product with immuno-stimulatory and immuno-regulatory 
effects (46). TLR9 is expressed by many cell types located in the intestine, including 
epithelial cells and dendritic cells, and subcutaneous administration of immuno-stimulatory 
9 
DNA has been reported to reduce the severity of experimental and spontaneous colitis in 
murine models of IBD (47) via a mechanism attributed to TLR9 signalling (48). 
 
A decrease in the secretion of pro-inflammatory cytokines, IFN-gamma, TNF-alpha and IL-
12, and interference with bacterial adherence to the epithelium has been demonstrated 
following probiotic administration, associated with NF-kappaB inhibition, heat-shock protein 
induction and proteasome inhibition, although NF-kappaB induction has also been 
demonstrated (49,50). Unexpectedly, many of these beneficial effects have been achieved not 
only by live bacteria, but also by gamma-irradiated non-viable bacteria, bacterial DNA 
components and probiotic-cultured media (49,51).  Investigations into probiotic supernatants 
and their therapeutic potential in IBD are therefore forming the basis for new directions in 
IBD research.  In summary, although mechanisms of probiotic action may vary, depending on 
the experimental or clinical context, and depending on differences in the host and in the 
bacterial strain, the engagement with host immunity is pivotal to probiotic action in IBD.  
 
Probiotics as therapeutic agents in IBD 
The human colon is a densely populated microbial ecosystem with several hundred bacterial 
species usually present with a total weight estimated to be several hundred grams (52). There 
are up to 1013–1014 total bacteria in the human intestinal tract, representing 10- to 20-fold 
more than the total number of tissue cells in the entire body, with most bacteria being obligate 
anaerobes, including clostridia, eubacteria, bacteroides groups and the genus bifidobacterium, 
such as Bifidobacterium bifidum and Bifidobacterium infantis (53). 
 
Probiotic efficacy has been confirmed in animal model studies by several investigators with 
different probiotic strains (37,53), although the use of probiotic therapy for IBD has only 
recently attracted serious interest from clinicians. Clinical trials in Crohn's disease with 
organisms, including lactobacillus (54) yeast (13), and coliforms (56), have been confounded 
by small patient numbers, differences in disease activity and variations in disease distribution 
(56). These deficiencies have been exacerbated by a growing, but poorly regulated, 
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commercial market for probiotics, often linked with somewhat tenuous, or exaggerated, 
claims for health benefits.  Historically, the stability, optimal dose-range, frequency of 
administration and vehicle for delivery, have rarely been determined. However, at present in 
Europe, well-designed and appropriately controlled trials of individual probiotic preparations 
are underway in both Crohn's disease and ulcerative colitis, to ascertain their efficacy in both 
active disease and in prevention of relapse. 
 
Individual probiotics and IBD treatment 
The predominant, potentially health-enhancing, bacteria in IBD are the bifidobacteria and 
lactobacilli, both of which belong to the lactic acid bacteria (LAB) group (57). These two 
genera do not include any significant pathogenic species and their dominance in the faeces of 
breast-fed babies is thought to impart protection against infection (58,59). Most commercially 
available probiotics meet minimum selection criteria including acid and bile resistance and 
survival during gastrointestinal transit, but an ideal individual probiotic strain for any given 
indication has still yet to be defined.  
 
Lactobacilli and bifidobacteria have traditionally been the most common candidates for 
probiotic-based treatments in IBD.  Although there is a growing body of scientific literature 
and a wealth of anecdotal information supporting the utility of lactobacillus strains as 
therapeutic agents in a range of alimentary disorders, progress has perhaps been hampered by 
poorly-controlled associations between probiotic administration and clearly-defined clinical 
end-points. Recently, Hawrelak et al (60) conducted a systematic review of six clinical trials 
investigating the capacity for Lactobacillus rhamnosus GG to prevent the onset of antibiotic-
associated diarrhoea. As data sources, these investigators employed computer-based searches 
of MEDLINE, CINAHL, AMED, the Cochrane Controlled Trials Register and the Cochrane 
Database of Systematic Reviews and the bibliographies of relevant papers and previous meta-
analyses. Four of the six trials found a significant reduction in the risk of antibiotic-associated 
diarrhoea with co-administration of Lactobacillus GG; one trial reported a reduced number of 
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days with antibiotic-induced diarrhoea, whilst the final trial found no benefit of Lactobacillus 
GG supplementation. These results are not unique in the context of retrospective probiotic 
studies, highlighting the need for additional research and the development of strictly-
controlled predictive systems to clarify the effectiveness of Lactobacillus-based treatments 
beyond the effects of LGG in prevention of antibiotic-associated diarrhoea. 
 
Bifidobacterium, a member of the dominant microbiota (i.e. >108–109 colony forming unit 
(CFU)/g, represent up to 25% of the cultivable faecal bacteria in adults and 80% in infants. 
As probiotic agents, bifidobacteria have been studied for their efficacy in the prevention and 
treatment of a broad spectrum of animal and/or human gastrointestinal disorders, such as 
colonic transit disorders, intestinal infections, and colonic adenomas and cancer (10). Indeed, 
certain strains (eg Bifidobacterium animalis strain DN-173 010) have been reported to 
prevent or alleviate infectious diarrhoea through effects on the immune system and resistance 
to colonization by pathogens and there is some evidence that certain bifidobacteria may 
actually protect the host from pro-carcinogenic activity of intestinal flora (10). 
 
Non-pathogenic Escherichia coli, especially the Nissle 1917 strain, have generated increasing 
reports of efficacy in the context of inflammatory disorders. In ulcerative colitis, the non-
pathogenic strain of E. coli Nissle demonstrates efficacy equivalent to that of mesalazine in 
ulcerative colitis (61,62). Kamada et al (63) utilising dextran sulphate sodium (DSS)-induced 
and IL-10 knock-out models of colitis have recently reported the non-pathogenic E. coli strain 
Nissle1917 to prevent both acute and chronic colitis, with its anti-inflammatory properties 
attributed not only to viable bacteria but also to heat-killed bacteria or its genomic DNA. 
Obermeier et al (64) demonstrated a pro-inflammatory effect of cytosin-guanosin dinucleotide 
(CpG)-oligodeoxynucleotide (ODN) treatment in established and chronic DSS-induced 
colitis, suggesting that DNA derived from luminal bacteria plays a role in the perpetuation of 
chronic intestinal inflammation. These investigators further speculated that treatment with 
adenoviral ODN (AV-ODN) could block the known CpG effects in IBD. The apparent 
discrepancy between bacterial DNA sources and effects on intestinal inflammation highlights 
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the need for well-controlled comparative studies of bacterial DNA, and, more specifically, 
CpG motifs, sourced from endogenous or probiotic bacteria. 
 
It should be noted, however, that probiotic properties have not been attributed solely to 
bacterial sources, since non-bacterial organisms, such as Saccharomyces boulardii, or even 
nematode parasites have been utilised for probiotic purposes (13,65) In summary, it seems 
unlikely that a single probiotic will be equally suited to all indications; selection of strains for 
disease-specific indications will be required, and it is in this capacity that well-conducted 
animal model studies will prove a valuable tool  
 
‘Designer’ probiotics 
Genetic modification of food-grade commensal bacteria will need to be accommodated into 
our concept of probiotics. To this end, the term "pharmabiotic" has been developed as a more 
appropriate generic or umbrella term to encompass any form of therapeutic exploitation of the 
commensal flora (66,67). Food-grade bacteria can be modified, or engineered, to achieve 
specific functional activity. This can include delivery of anti-inflammatory cytokines or other 
biologically active molecules and vaccines to the gut. Of relevance to IBD, the food grade 
organism Lactococcus lactis, has been engineered to secrete IL-10 locally within the gut (68). 
When tested in two animal models of IBD, the magnitude of this effect was equivalent to 
corticosteroid therapy in its ability to decrease inflammation and disease severity. Another 
example of the potential applications of engineered commensal organisms is the genetic 
modification of lactobacilli resident within the female genital tract to express functional two-
domain CD4 in order to confer protection against HIV infectivity in vitro (69). The future 
scope for this strategy is limitless, but public health and other safety concerns must be 
resolved before routine clinical use in humans can be instigated. Other examples of 
genetically modified (GM) microbes include the delivery of single-chain antibodies for 
pathogen-specific passive immunity (70,71) and bacterial-derived trefoil factors to promote 
healing and repair in the inflamed mouse gut (72).   
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Recently, Inglis et al (73) in a rodent model of intestinal mucositis, utilising the recently-
developed non-invasive sucrose breath test, described a decrease in small intestinal 
inflammation following administration of the folic-acid secreting probiotic, Streptococcus 
thermophilus TH-4. Although not tested directly, these investigators speculated that the 
‘trickle’-delivery of S. thermophilus TH-4 sourced folate to the intestinal enterocytes may 
have reduced the severity of intestinal damage induced by the folate depletion, and resulting 
inhibition of DNA synthesis, manifest by methotrexate-based chemotherapy.  Similarly, Geier 
et al (74) have described a partial reduction of colonic inflammation in a rodent model system 
utilising Lactobacillus fermentum BR11 reportedly via its unique capacity to modify the 
cystine/cysteine equilibrium and hence, reduce oxidative stress. 
 
Public health concerns in relation to the release of genetically-modified organisms into the 
environment have replaced technological constraints as the major hurdles to be overcome with 
genetically-modified bacteria, and bio-containment has emerged as an environmental priority 
(75). Nevertheless, it would appear highly likely that future probiotic studies will be focussed 
not only on exploiting their existing beneficial properties, but also their capacity to deliver a 
broad range of specific factors, ranging from vitamins and antibodies through to strategically-
developed, genetically-modified agonists and inhibitors. 
 
Probiotic mixtures and formulations 
Simple ingestion of a broad spectrum of probiotics would appear to be a pragmatic approach 
to cover a range of different indications and individual variations in host flora, although this 
would assume that individual probiotic constituents are not mutually antagonistic. 
Furthermore, it is a fundamental principle of therapeutic development that the properties and 
optimal usage of individual components of any mixture or formulation should be 
comprehensively determined before they can be recommended in combination. Undoubtedly, 
however, the most compelling evidence for probiotic efficacy in IBD has been reported with a 
combination of eight bacterial strains in the maintenance of remission of active ulcerative 
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colitis (76) and prevention of pouchitis (77). This combination, termed VSL#3, comprises 
four strains of lactobacilli and three strains of bifidobacteria, together with Streptococcus 
thermophilus.  Indeed, there is now a sizeable scientific literature on VSL#3 and its 
application for a growing number of clinical disorders, with a recent report indicating 
hydrolytic activity against gliadin polypeptides suggesting a possible application for VSL#3 
in the control of coeliac disease (78). 
 
Rachmilewitz et al (48) have reported anti-inflammatory effects of VSL#3 in murine 
experimental colitis, mediated by Toll-like receptor (TLR9) signalling. Importantly, these 
authors described that intragastric and subcutaneous administration of probiotic DNA 
ameliorated the severity of experimental colitis, whereas methylated probiotic DNA, calf 
thymus DNA, and DNase-treated probiotics had no effect. Moreover, colitis severity was 
attenuated to the same extent by intragastric delivery of non-viable, gamma-irradiated, or 
viable probiotics, suggesting that the protective effects of probiotics are mediated by their 
own DNA rather than by their metabolites or ability to colonize the colon. The finding that 
live micro-organisms were not required to attenuate experimental colitis holds significant 
implications for the further development of probiotics as prophylactics or therapeutics in IBD. 
The development of further probiotic combinations for IBD treatment appears highly likely, 
although the current strategy will remain somewhat empirical until better-defined predictive 
in vivo and in vitro systems have been developed.  
 
The emergence of more compelling pre-clinical data from well-controlled animal model 
studies is therefore proving to be a positive strategy for probiotic efficacy studies in 
prospective IBD research. Such a strategy, in the absence of a rigorous, rapid throughput in 
vitro screening assay, will become vital given the likely complexity of probiotic formulations 
comprising mixtures of currently-characterised and newly-developed ‘designer’ probiotics. 
To test the matrix of probiotic formulations in human clinical trials, even if conducted 
strategically, would clearly be impossible. 
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Prebiotics and Synbiotics  
Prebiotics are defined as non-digestible food ingredients that beneficially affect the host by 
selectively stimulating the growth of bacterial species already established in the colon and 
thus improve host health (79). These are usually of a poly- or oligo-saccharide nature with 
studies largely confined to fructo-oligosaccharide (FOS), galacto-oligosaccharide (GOS) and 
maltodextrin (80). The health interest of the Bifidobacterium genus is reflected in the 
commonly-accepted definition of prebiotics: food ingredients that selectively stimulate the 
growth and activity of bacteria in the gut, usually bifidobacteria (bifidogenic effect) and 
lactobacilli, thereby producing health benefits.  
 
Although an exhaustive review of prebiotics is beyond the scope of this review, the 
importance of identified prebiotics in combination with dead or live probiotics (synbiotics), or 
biologically active bacterial metabolites, should not be under-stated.  For example, Kanauchi 
et al (81) have recently described a synbiotic combination of germinated barley foodstuff 
(GBF) and Eubacterium limosum (E. limosum) and its potential as an adjunctive treatment for 
IBD. Although probiotic approaches for IBD include VSL#3, Nissle1917, Clostridium 
butyricum, and Bifidobacterium-fermented milk, Eubacteria have not been studied to any 
great extent. E. limosum is a commensal micro-organism that is promoted by GBF 
administration, and its metabolites include butyrate, which can accelerate intestinal epithelial 
growth and inhibit IL-6 production. GBF is therefore a prebiotic, and its unique 
characteristics make it highly suitable for applications in IBD. GBF prolongs remission in 
ulcerative colitis patients and also attenuates clinical activity in non-remissive colitic patients.  
 
The further complexity of incorporating the increasing development and number of prebiotics 
into the expanding range of newly-developed probiotic formulations described previously, 
greatly increases the number of synbiotic combinations which await testing in pre-clinical 
systems. However, although this enormous number of synbiotics and designer synbiotics may 
be intimidating from a pre-clinical efficacy perspective, there exists the increased potential to 
identify greater numbers of promising, efficacious candidate treatment formulations for IBD. 
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Combining this strategy with genetic and genomic approaches to define IBD susceptibility 
and probiotic responsiveness could ultimately result in individually-tailored probiotic-based 
treatment approaches in IBD. 
 
Personalised probiotics 
Optimal selection of a probiotic may even need to take into account individual variations in 
host diet and composition of gut flora. In this respect, the apparent influence of human genetic 
variability on intestinal bacterial composition is particularly intriguing (82). Furthermore, it 
seems unlikely that a single probiotic will be equally suited to all conditions. As a 
consequence, selection of strains for disease-specific indications will be required (27).  It is 
beginning to become apparent that our definition of probiotics may be somewhat simplistic 
since there are indications a probiotic under certain circumstances, may not be a probiotic at 
all under altered physiological or pathogenic states, or even in different hosts.  Different 
probiotics have distinct properties, and not all models of experimental colitis respond to the 
same probiotics (83).  Almost certainly, there will not be a ‘one size fits all’ approach to 
probiotic use in IBD. Personalised, designer probiotics and synbiotics could therefore be a 
real therapeutic option for IBD sufferers in the future. 
 
Conclusions 
Probiotics continue to hold great promise for IBD treatment and prevention, but despite some 
significant advances, it would be fair to say that this field of research is still in its infancy. 
Understanding the mechanisms responsible for the beneficial effect of probiotics in 
inflammatory bowel disease and experimental colitis will aid our understanding of the role of 
endogenous and exogenous bacteria in IBD aetiology and pathogenesis. The finding that live 
probiotics may not be essential for therapeutic effects, and that these effects may also be 
obtained by the systemic route of administration, could have a major impact on the use and 
manufacture of probiotics.  Phenotypic and genomic characterisation of probiotic strains will 
be required, together with clarification of their mechanisms of action across a broad range of 
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rigorously-controlled clinical settings. Moreover, results of probiotic studies demonstrating 
efficacy in a given clinical setting should not be extrapolated to other disease indications 
without separate controlled assessments.   
 
Over the past decade, there have been quantum advances in probiotic-based research in IBD.  
Initial, largely anecdotal, reports of lactobacillus efficacy have been replaced by the 
development of specific ‘designer’ probiotics, which together with identified prebiotics, could 
result in a significant repertoire of designer synbiotics for IBD treatment. Such an array of 
treatment options, combined with genetic advances in IBD susceptibility and probiotic 
responsiveness, could eventually result in the exciting emergence of individually-tailored 
probiotic-sourced formulations.  The major challenge in the short-term will be the 
development of rigorous in vivo and in vitro testing systems to rapidly determine the 
suitability of any given probiotic-based formulation, not only to a specific condition, but also 
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